• Perceptive allies with Garabedian on $210M early-stage fund

    9 monthes ago - By Fierce Biotech

    Perceptive Advisors is moving into early-stage biotech investments in partnership with ex-Sarepta Therapeutics CEO Chris Garabedian. The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences, reflecting its plans to take the lead on early-stage investments.
    Read more ...

     

  • Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs

    Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs

    9 monthes ago - By Xconomy

    Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at the earliest stages with a new $210 million venture capital fund. The Perceptive Xontogeny Venture Fund is led by Chris Garabedian , a veteran biotech executive whose experience includes stops at Gilead Sciences , Celgene, and Sarepta Therapeutics. He's currently the chairman and CEO of Xontogeny, a Boston-based life sciences accelerator. PXV will favor investments in companies emerging from Xontogeny, which already...
    Read more ...